Poland· PL-100125827
Reyataz
A atazanavir product containing atazanaviri sulfas, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Atazanavir is registered in 17 of 19 countries.
Countries holding a registration under ATC J05AE08 (atazanavir), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Atazanavir · ATC J05AE08
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of atazanavir costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Atazanavir · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$14.11
The record
At a glance
URPL (Poland)- Active substance
- Atazanaviri sulfas
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Poland (PL)
- ATC code
- J05AE08
- ATC class
- Atazanavir
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990002146
- gtin05909990002153
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for atazanavir.
Graded by severity as the source publishes them — 135 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Atazanavir · interactions on record
429 records
- 135 severe
- 204 moderate
- 14 minor
- 50 info
Most severe, free to view
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- NizatidineA02BA04severe
26 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Atazanavir in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsAtazanavir Accord 150 mg harde capsulesAccord Healthcare B.V.
- CzechiaATAZANAVIR VIATRISVIATRIS LIMITED, Dublin
- FinlandAtazanavir KrkaKRKA d.d. Novo mesto
- BelgiumAtazanavir Krka 150 mgKRKA d.d. Novo mesto
- SpainATAZANAVIR ACCORD 150 MG CAPSULAS DURAS EFGAccord Healthcare S.L.U.
- FranceATAZANAVIR BIOGARAN 150 mg, géluleBIOGARAN
- SwedenAtazanavir Krka 150 mg Kapsel, hårdKrka d.d., Novo mesto
- United StatesAtazanavirLaurus Labs Limited
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Cyprus · Atazanavir Remedica
- Czechia · Atazanavir Accord
- Germany · Atazanavir Accord, Atazanavir Al
- Denmark · Atazanavir Stada
- Spain · Atazanavir Stada, Atazanavir Teva
- Finland · Atazanavir Stada
- France · Atazanavir Arrow, Atazanavir Biogaran
- United Kingdom (Northern Ireland) · Atazanavir Accord, Atazanavir Amarox
- Croatia · Atazanavir Accord
- Ireland · Atazanavir Rowex
- Iceland · Atazanavir Stada, Atazanavir Stada 150 Mg Hörð Hylki
- Italy · Atazanavir Sandoz
- Liechtenstein · Atazanavir Viatris, Reyataz
- Latvia · Atazanavir Sandoz
- Netherlands · Atazanavir Accord, Atazanavir Medicopharm
- Norway · Atazanavir Viatris, Reyataz
- Portugal · Atazanavir Farmoz, Atazanavir Generis
- Romania · Atazanavir Stada, Atazanavir Teva
- Sweden · Atazanavir Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c3c6f2cb-3a1e-4e4c-825c-ecf8d70b7514 GET /v1/drugs/c3c6f2cb-3a1e-4e4c-825c-ecf8d70b7514?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "150 mg",
"packaging": "05909990002146 ¦ Rpz ¦ EU/1/03/267/003 ¦ 23845\n1 butelka 60 kaps.\n05909990002153 ¦ Rpz ¦ EU/1/03/267/004 ¦ 23846\n60 kaps. w blistrach",
"substance": "Atazanaviri sulfas 150 mg",
"common_name": "Atazanaviri sulfas",
"pl_product_id": "100125827",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": "2024-09-05"
}See everything about atazanavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.